Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
TRVI Stock Chart & Stats
$13.47
<$0.01(0.12%)
At close: 4:00 PM EST
$13.47
<$0.01(0.12%)
Day’s Range― - ―
52-Week Range$3.77 - $14.39
Previous CloseN/A
Volume226.18K
Average Volume (3M)2.56M
Market Cap
$1.44B
Enterprise Value$1.31B
Total Cash (Recent Filing)$194.93M
Total Debt (Recent Filing)$823.00K
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Mar 25, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding128,230,130
10 Day Avg. Volume1,820,513
30 Day Avg. Volume2,561,308
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)4.18
Price to Sales (P/S)0.00
P/FCF Ratio-10.87
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-34.41K
Enterprise Value/Ebitda-28.59
Forecast
1Y Price Target
$21.22Price Target Upside57.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Indication Expansion And Commercial PotentialPlanned trials in non-IPF interstitial lung diseases and refractory chronic cough, along with analyst expectations of a standalone chronic cough franchise, broaden Haduvio's commercial opportunity.
Regulatory ClarityFDA scheduling of an End-of-Phase 2 meeting clarifies the regulatory pathway and supports plans to initiate a pivotal Phase 3 program for Haduvio in IPF-associated chronic cough.
Safety And Drug Interaction ProfileSafety review observed no respiratory depression in sentinel cohorts and drug-drug interaction testing showed no meaningful interactions with standard IPF therapies, reducing safety concerns for combination use.
Bears Say
Additional Pre‑pivotal WorkRequirement for additional Phase 1 and drug‑interaction studies before initiating a full Phase 3 program increases development workload and pushes back pivotal readiness.
Delayed Data TimelinePlanned studies are not expected to report results until 2027, creating an extended period of clinical-data uncertainty that may damp investor confidence.
Reimbursement And Funding RiskUncertainty about reimbursement, competitive pressure, and the potential need for additional capital raise the risk of pricing pressure or shareholder dilution ahead of commercialization.
Trevi Therapeutics News
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $3.77 and its highest was $14.39 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Trevi Therapeutics Inc’s market cap is $1.44B.
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is Mar 25, 2026 which is in 41 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on Nov 13, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.098 by $0.018.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -0.1.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 128,230,130 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.098. Following the earnings report the stock price went down -0.785%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Currently, no hedge funds are holding shares in TRVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Trevi Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.22 (57.55% Upside)
$21.22 (57.55% Upside)
Hedge Fund Trend
Decreased
By 351.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 11.8%
Last 30 Days ▼ 11.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
232.05%
12-Months-Change
Fundamentals
Return on Equity
-36.87%
Trailing 12-Months
Asset Growth
182.26%
Trailing 12-Months
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
TRVI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, with Trevi Therapeutics reporting successful trial data, financial stability, and strategic plans to expand their market opportunities. Although there were some financial losses and regulatory challenges, the company's advancements and cash reserves suggest a promising outlook.View all TRVI earnings summariesTRVI Stock 12 Month Forecast
Average Price Target
$21.22
▲(57.55% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
11.71% Insiders
12.58% Mutual Funds
1.13% Other Institutional Investors
64.94% Public Companies and Individual Investors